Valenti, Luca http://orcid.org/0000-0001-8909-0345
Corradini, Elena
Adams, Leon A.
Aigner, Elmar
Alqahtani, Saleh
Arrese, Marco
Bardou-Jacquet, Edouard
Bugianesi, Elisabetta
Fernandez-Real, Jose-Manuel http://orcid.org/0000-0002-7442-9323
Girelli, Domenico http://orcid.org/0000-0001-9684-1899
Hagström, Hannes
Henninger, Benjamin
Kowdley, Kris
Ligabue, Guido http://orcid.org/0000-0001-9304-0703
McClain, Donald http://orcid.org/0000-0002-3310-2359
Lainé, Fabrice
Miyanishi, Koji http://orcid.org/0000-0002-6466-3458
Muckenthaler, Martina U.
Pagani, Alessia
Pedrotti, Patrizia
Pietrangelo, Antonello
Prati, Daniele
Ryan, John D.
Silvestri, Laura
Spearman, C. Wendy http://orcid.org/0000-0003-3199-301X
Stål, Per
Tsochatzis, Emmanuel A. http://orcid.org/0000-0001-5069-2461
Vinchi, Francesca
Zheng, Ming-Hua http://orcid.org/0000-0003-4984-2631
Zoller, Heinz http://orcid.org/0000-0003-1794-422X
Article History
Accepted: 19 January 2023
First Online: 17 February 2023
Change Date: 14 December 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41574-023-00940-2
Competing interests
: L.V. has received speaking fees from MSD, Gilead, AlfaSigma and AbbVie, served as a consultant for Gilead, Pfizer, AstraZeneca, Novo Nordisk, Intercept Pharmaceuticals, Diatech Pharmacogenetics and Ionis Pharmaceuticals, and received research grants from Gilead. E.C. has received speaking fees from Vifor Pharma and Sanofi–Genzyme, and served as a consultant for Vifor Pharma and Kedrion Biopharma. L.A.A. has been on advisory boards for Pfizer, Novartis and Roche Diagnostics. E.A. has received speaking and/or consultancy fees from Sanofi, Gilead Sciences, Intercept Pharmaceuticals, Roche, Novartis, Amgen, Novo Nordisk, Alnylam Pharmaceuticals, Sanofi–Aventis, Vifor, Daiiki–Sanyo, Sobi, PharmGenetix, Takeda. E.B. advises on Gilead, Pfizer, Novo Nordisk, Intercept, Inventiva, MSD, Boehringer and received a research grant from Gilead. E.B.-J. received speaking fees from Gilead, AbbVie and Orphalan. H.H.’s institution has received research grants from AstraZeneca, EchoSens, Gilead, Intercept, MSD and Pfizer with H.H. as a PI. These are unrelated to the current study. K.K. advises, is on the speakers’ bureau for, and received grants from Gilead, Intercept, HighTide. K.K. consults for Altimmune, Roche and Boeringer Ingelheim. K.K. advises Assembly and Calliditas. K.K. is on the speakers’ bureau for AbbVie. K.K. received grants from Janssen, Allergan, Genfit, CymaBay, Novartis, Enanta, Protagonist, Pfizer, BMS, Celgene, Intercept, Madrigal and Viking. D.P. advises for, has received speaking fees or travel/research grants from Macopharma, Ortho Clinical Diagnostics, Grifols, Gilead, Terumo, Immucor, Diamed, Diatech Pharmacogenetics and Diasorin. J.D.R. received consulting fees from Pfizer, Alnylam, 5am Ventures, Bond Biosciences, Gilead, Kyowa Kirin. P.S. has received speaking fees from MSD, Eisai, Roche and Albireo. C.W.S. has received speaking fees from Gilead and Abbott. E.A.T. has served as a consultant for Alexion, Boehringer, Gilead, Intercept, Novo Nordisk, Orphalan and Pfizer. M.H.Z. has received speaking fees from Hisky Medical. F.V. receives research grants from Vifor, Pharmanutra and Silence Therapeutics. H.Z. has received speaking fees from AbbVie, BMS, Bayer, Gilead, Intercept, Eisai, Sanofi–Genzyme, Vifor, Pharmacosmos, Medice, Pierre-Fabre, the Falk Foundation and grant support from Pharmacosmos and Vifor. The authors declare that none of these conflicts of interest is relevant to the present article. The other authors declare no competing interests.
Free to read: This content has been made available to all.